Beyond CDK4/6 Inhibition: Putting New Data on Targeting the PI3K Pathway Into Clinical Practice

Download this slideset to review the latest clinical data on the evolving role of mTOR and PIK3 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Hope S. Rugo, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 710 KB
Released: December 11, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Immunomedics, Inc.
Lilly

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

First-line pembrolizumab + chemotherapy significantly improved OS vs chemotherapy alone in locally recurrent unresectable or metastatic TNBC with PD-L1 CPS ≥10, from ESMO 2021 as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Novel ADC [vic]-trastuzumab duocarmazine significantly prolonged PFS vs physician’s choice treatment in pretreated HER2+ advanced or metastatic breast cancer, presented at ESMO as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue